<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of budesonide therapy for adults with inflammatory bowel disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of budesonide therapy for adults with inflammatory bowel disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of budesonide therapy for adults with inflammatory bowel disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Peppercorn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam S Cheifetz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> is a glucocorticoid with high first-pass metabolism; thus, the systemic bioavailability of the drug is decreased. This topic will review the pharmacology, indications, dosing, and safety of budesonide in the management of chronic, inflammatory bowel disease (IBD). The efficacy of budesonide for treating adult patients with Crohn disease, ulcerative colitis, pouchitis, or microscopic colitis, and the approach to medical management for these conditions are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/93857.html" rel="external">"Management of acute and chronic pouchitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="headingAnchor" id="H201639199"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H377832541"><span class="h2">Metabolism</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> is a glucocorticoid that is metabolized in the liver via cytochrome P450 isoenzyme CYP3A4 into two metabolites: 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide [<a href="#rid1">1</a>]. </p><p>Approximately 90 percent of orally administered <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> undergoes first-pass metabolism resulting in low systemic bioavailability of 10 to 15 percent [<a href="#rid1">1-6</a>]. The low systemic effect of budesonide results in less effect on adrenal function and bone mass compared with conventional glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) [<a href="#rid7">7</a>]. (See <a class="local">'Adverse effects'</a> below.)</p><p>Factors that interfere with drug metabolism and may lead to increases in systemic bioavailability by two- to eight-fold include:</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent use of moderate and strong inhibitors of CYP3A4 such as <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> or grapefruit juice  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 1</a>) [<a href="#rid8">8,9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Cirrhosis of the liver [<a href="#rid3">3</a>].</p><p></p><p>To assess specific drug interactions, the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate can be used.</p><p class="headingAnchor" id="H2853593112"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> has high topical anti-inflammatory activity and may work by depressing the activity of endogenous chemical mediators of inflammation (eg, kinins, prostaglandins). Glucocorticoids such as budesonide inhibit protein synthesis and transcription and downregulate the production of inflammatory cytokines [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H165108042"><span class="h2">Formulation characteristics</span></p><p class="headingAnchor" id="H3821049447"><span class="h3">Oral formulations</span><span class="headingEndMark"> — </span>In its native form without an encapsulation system, <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is absorbed in the proximal small bowel. Oral budesonide formulations are engineered to be resistant to gastric acid and allow for targeted, pH-dependent budesonide release, and they include  (<a class="graphic graphic_table graphicRef116034" href="/d/graphic/116034.html" rel="external">table 2</a>) [<a href="#rid1">1,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ileal release formulations</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Controlled ileal release formulation (CIR, pH- and time-dependent release)</strong> – The controlled ileal release formulation is a gelatin capsule filled with enteric coated granules that dissolve at a pH ≥5.5. This facilitates drug delivery to the ileum and ascending colon. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>pH-dependent release formulation</strong> – This pH-dependent release formulation (not available in the United States or Canada) is a gelatin capsule containing <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> pellets coated with methacrylic polymers. This formulation delivers the drug at pH &gt;6.4 in the ileum and ascending colon.</p><p></p><p class="bulletIndent1">Either controlled ileal release or pH-dependent release formulations may be used for treating patients with Crohn disease, and the choice between the two formulations is based on availability [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults", section on 'Budesonide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colonic release formulation</strong> – This formulation of multimatrix <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> extends its delivery to the entire colon and is used for treating patients with mild to moderate ulcerative colitis. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Subsequent therapy'</a>.)</p><p></p><p class="bulletIndent1">Colonic release <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is covered in a coating that resists gastric acid and dissolves at a pH ≥7. When the tablet reaches an alkaline environment, the coating dissolves and intestinal fluid comes into contact with the hydrophilic matrix. The matrix then swells and gradually dissolves, thereby releasing budesonide throughout the colon. </p><p></p><p class="headingAnchor" id="H1420912138"><span class="h3">Rectal formulations</span><span class="headingEndMark"> — </span>Rectal formulations include <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> liquid enema and budesonide foam. Liquid enemas reach the proximal sigmoid colon and splenic flexure in patients who are able to retain them. In contrast, foam preparations generally reach the mid-sigmoid colon. Foam preparations are easier to retain compared with liquid enemas, especially in patients with rectal inflammation resulting in decreased rectal compliance.</p><p class="headingAnchor" id="H2961449102"><span class="h2">Timing of response</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> is generally a fast-acting drug. A clinical response is typically observed after 7 to 10 days of therapy with either the oral formulation or the topical preparations. </p><p class="headingAnchor" id="H2095429953"><span class="h1">CONTRAINDICATIONS AND CAUTIONS</span></p><p>Patients who require special consideration include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with cirrhosis</strong> – We avoid using <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> for patients with cirrhosis because of a greater than two-fold increase in systemic bioavailability in these patients (compared with patients without liver disease) and possible increased risk of adverse effects related to systemic glucocorticoids [<a href="#rid3">3</a>]. (See <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on CYP3A inhibitors </strong>– The combination of <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> and a CYP3A inhibitor (eg, <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> or grapefruit juice) is used with caution because drugs (or substances) that inhibit CYP3A enzymes may increase the serum concentration of budesonide. (See <a class="local">'Metabolism'</a> above.)</p><p></p><p>For specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate. </p><p class="headingAnchor" id="H3563187823"><span class="h1">DOSING</span></p><p class="headingAnchor" id="H2151013969"><span class="h2">Oral formulations</span></p><p class="headingAnchor" id="H589738551"><span class="h3">Starting dose and subsequent taper</span><span class="headingEndMark"> — </span>The starting dose and subsequent tapering schedule of the oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> formulations (eg, controlled ileal release form, budesonide multimatrix [MMX]) generally begins with budesonide 9 mg taken daily. For example, in patients with ulcerative colitis, we give budesonide MMX 9 mg daily for 6 to 12 weeks. If symptoms of active IBD such as diarrhea and rectal bleeding improve with treatment, the budesonide dose is reduced to 9 mg every other day for two to four weeks, followed by discontinuation. Budesonide is used to induce, but not maintain, remission. (See <a class="local">'Oral formulations'</a> above.)</p><p>If the patient does not respond after four weeks of <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> 9 mg daily, a change in drug therapy is usually required. Subsequent drug selection depends on a number of factors including the severity and location of disease. The management of patients who do not respond to budesonide MMX, in addition to the approach to induction and maintenance therapy for ulcerative colitis, are discussed separately. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.) </p><p>For patients with Crohn disease, the initial dosing regimen typically begins with oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> 9 mg taken daily for four to eight weeks, followed by a taper, for a total of 8 to 12 weeks of therapy. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p>Disease activity is assessed clinically by observing a change in symptoms. Serum and stool markers of inflammation (eg, C-reactive protein, fecal calprotectin) should also be obtained to assess response. (See  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a>.)</p><p>We try to limit <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> to a single course. Therapeutic options for patients whose symptoms improve initially but then flare when budesonide is tapered or discontinued are discussed separately. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Induction of remission'</a>.) </p><p>The goal of tapering is to use a rate of change in dosing that will permit observation of the early signs of a disease flare. </p><p class="headingAnchor" id="H3769553163"><span class="h3">Other instructions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> capsules should be swallowed whole and cannot be chewed or crushed [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1039167423"><span class="h2">Rectal formulations</span><span class="headingEndMark"> — </span>Rectal <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> formulations are used for treating symptoms of diarrhea, tenesmus, urgency, and rectal bleeding in patients with ulcerative proctosigmoiditis or left-sided ulcerative colitis [<a href="#rid12">12,13</a>]. Dosing depends on whether the budesonide is given as a rectal foam or an enema, and neither preparation requires tapering [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Rectal foam (2 mg per application) – Initial therapy with <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> foam can be given once or twice daily for two weeks followed by once daily therapy for four weeks. Response to treatment is assessed clinically by observing a change in symptoms as well as serum and stool markers of inflammation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enema (2 mg per 100 mL application, available in Canada only) – Initial therapy is given once daily at bedtime for four weeks. If symptoms do not improve, daily enema therapy at bedtime may continue for an additional four weeks. </p><p></p><p>The management of patients with ulcerative colitis who do not respond to topical therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p class="headingAnchor" id="H1333722138"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>We do not routinely monitor patients on <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> for glucocorticoid-related adverse (eg, hyperglycemia or osteoporosis) because of the low systemic bioavailability of budesonide and its use as induction therapy (maximum treatment duration of three months) [<a href="#rid14">14</a>]. </p><p class="headingAnchor" id="H252515107"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H3990804078"><span class="h2">Frequency of adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> has an overall excellent safety profile and is associated with fewer adverse effects compared with conventional glucocorticoids [<a href="#rid15">15,16</a>]. In a pooled analysis of three studies including over 900 patients with ulcerative colitis, the risk of having at least one adverse event was not significantly different for patients receiving budesonide multimatrix formulation compared with placebo (RR 1.09, 95% CI 0.95-1.26) [<a href="#rid15">15</a>]. </p><p>Systemic adverse effects (eg, adrenal suppression, decreased bone mass) occur less often in patients treated with <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> compared with conventional glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) due to location-specific delivery and a high first-pass metabolism resulting in limited systemic bioavailability (10 to 15 percent) [<a href="#rid7">7,14,16-19</a>]. (See <a class="local">'Pharmacology'</a> above.)</p><p class="headingAnchor" id="H5"><span class="h2">Effect on bone mineral density</span><span class="headingEndMark"> — </span>While systemic glucocorticoid therapy is associated with an appreciable risk of bone loss, the available data suggest that <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> has limited effect on bone mineral density because of its low systemic bioavailability [<a href="#rid18">18,20,21</a>]. (See <a class="local">'Metabolism'</a> above.) </p><p>In particular, <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> therapy is associated with better preservation of bone mineral density in patients who are glucocorticoid-naïve prior to receiving budesonide. In a trial including 272 patients with Crohn disease involving the ileum and/or ascending colon, no significant differences were observed in bone mineral density at two-year follow-up between budesonide-treated patients compared with patients on <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> [<a href="#rid18">18</a>]. However, the reduction in bone mineral density was significantly less in patients who had never before received glucocorticoids and were subsequently treated with budesonide compared with those receiving prednisolone. </p><p>Despite this potential benefit of <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, patients with IBD may have other risk factors for osteoporosis including disease-related inflammatory activity, nutritional deficiency, hypogonadism, and prior use of systemic glucocorticoids. The risk factors for and treatment of metabolic bone disease in patients with IBD are discussed separately (see  <a class="medical medical_review" href="/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>).</p><p>The clinical features and evaluation of glucocorticoid-induced bone loss are discussed separately. (See  <a class="medical medical_review" href="/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Hypothalamic-pituitary-adrenal (HPA) axis suppression</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> can reduce the response of the HPA axis to stress, but to a lesser extent compared with conventional glucocorticoids [<a href="#rid16">16,22</a>]. In addition, supplementation with a systemic glucocorticoid may be required in patients taking budesonide who undergo surgery or other stressful situations (eg, bacterial sepsis). (See  <a class="medical medical_review" href="/d/html/146.html" rel="external">"The management of the surgical patient taking glucocorticoids"</a> and  <a class="medical medical_review" href="/d/html/7983.html" rel="external">"Glucocorticoid withdrawal"</a>.) </p><p>The approach to withdrawal of glucocorticoids, HPA suppression, and the clinical manifestations of adrenal insufficiency are presented separately. (See  <a class="medical medical_review" href="/d/html/7983.html" rel="external">"Glucocorticoid withdrawal"</a> and  <a class="medical medical_review" href="/d/html/124.html" rel="external">"Pharmacologic use of glucocorticoids"</a> and  <a class="medical medical_review" href="/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p class="headingAnchor" id="H201639219"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> is considered low risk in pregnancy and is used for the same indications as a nonpregnant patient with IBD. While we use budesonide for females with IBD throughout pregnancy, we counsel patients that there is a possible, albeit rare, risk of cleft palate described with conventional glucocorticoids given during the first trimester [<a href="#rid23">23-26</a>]. (See  <a class="medical medical_review" href="/d/html/6769.html" rel="external">"Etiology, prenatal diagnosis, obstetric management, and recurrence of cleft lip and/or palate"</a>.) </p><p>Throughout pregnancy, the lowest possible dose of <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> necessary for symptom control is given. Alternatives to budesonide include initiating biologic therapy, and these issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults", section on 'Maintenance of remission'</a> and  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p>Limited data suggest that <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is well tolerated in pregnant females with IBD and is not associated with increased risk of adverse outcomes. In a small study of eight pregnant females with Crohn disease who were treated with budesonide, there were no cases of maternal adrenal suppression, glucose intolerance, ocular side effects, hypertension, or fetal congenital abnormalities [<a href="#rid27">27</a>].</p><p><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> is compatible with breastfeeding. The side effects of glucocorticoids and the safety of glucocorticoids in pregnancy and lactation are discussed in detail, separately. (See  <a class="medical medical_review" href="/d/html/4083.html" rel="external">"Fertility, pregnancy, and nursing in inflammatory bowel disease", section on 'Glucocorticoids'</a>.)</p><p class="headingAnchor" id="H3307033834"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109937.html" rel="external">"Society guideline links: Ulcerative colitis in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/109856.html" rel="external">"Society guideline links: Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H427217462"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15383.html" rel="external">"Patient education: Crohn disease in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2004.html" rel="external">"Patient education: Crohn disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> is a glucocorticoid that is metabolized in the liver via cytochrome P450 isoenzyme CYP3A4 into two metabolites: 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide [<a href="#rid1">1</a>]. Approximately 90 percent of orally administered budesonide undergoes first-pass metabolism resulting in low systemic bioavailability of 10 to 15 percent. (See <a class="local">'Metabolism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulations</strong> – Without an encapsulation system, <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> is absorbed in the proximal small bowel and cannot be delivered to the site of inflammation. Oral budesonide formulations are engineered to be resistant to gastric acid and allow for targeted, pH dependent drug release. Available formulations include  (<a class="graphic graphic_table graphicRef116034" href="/d/graphic/116034.html" rel="external">table 2</a>) (see <a class="local">'Oral formulations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Controlled ileal release formulation (pH- and time-dependent release)</p><p class="bulletIndent2"><span class="glyph">•</span>pH-dependent release formulation (not available in the United States or Canada)</p><p class="bulletIndent2"><span class="glyph">•</span>Colonic release formulation (multimatrix formulation)</p><p></p><p class="bulletIndent1">Rectal formulations include <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> liquid enema and budesonide foam. Liquid enemas reach the proximal sigmoid colon and splenic flexure in patients who are able to retain them. In contrast, foam preparations generally reach the mid-sigmoid colon. (See <a class="local">'Rectal formulations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – We avoid using <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> for patients with cirrhosis because of a greater than two-fold increase in systemic bioavailability in these patients. (See <a class="local">'Contraindications and cautions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> (see <a class="local">'Dosing'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Crohn disease – For patients with Crohn disease, the initial dosing regimen is oral <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> 9 mg taken daily for four to eight weeks, followed by a taper, for an 8- to 12-week course of therapy. (See <a class="local">'Dosing'</a> above and  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ulcerative colitis – For patients with ulcerative colitis, we give <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> MMX 9 mg daily for 6 to 12 weeks. If symptoms such as diarrhea and rectal bleeding improve with treatment, the budesonide dose is reduced to 9 mg every other day for two to four weeks, followed by discontinuation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> has an overall excellent safety profile. Systemic adverse effects (eg, bone loss, adrenal suppression) occur less often in patients treated with budesonide compared with conventional glucocorticoids due to location-specific delivery and a high first-pass metabolism resulting in limited systemic bioavailability. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> is considered low risk in pregnancy and is used for the same indications as a nonpregnant patient with inflammatory bowel disease. The lowest possible dose of budesonide necessary to control symptoms is given. Alternatives to budesonide include initiating biologic therapy. (See <a class="local">'Pregnancy'</a> above and  <a class="medical medical_review" href="/d/html/4083.html" rel="external">"Fertility, pregnancy, and nursing in inflammatory bowel disease"</a>.)</p><p></p><p class="headingAnchor" id="H1757711228"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abdalla MI, Herfarth H. Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother 2016; 17:1549.</a></li><li><a class="nounderline abstract_t">Nunes T, Barreiro-de Acosta M, Marin-Jiménez I, et al. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis 2013; 7:183.</a></li><li><a class="nounderline abstract_t">Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004; 43:803.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021324s016lbl.pdf (Accessed on August 27, 2018).</li><li class="breakAll">https://www.medicines.org.uk/emc/product/138/smpc (Accessed on August 27, 2018).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203634s004lbl.pdf (Accessed on August 27, 2018).</li><li><a class="nounderline abstract_t">Iborra M, Alvarez-Sotomayor D, Nos P. Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014; 7:39.</a></li><li><a class="nounderline abstract_t">Seidegård J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. Clin Pharmacol Ther 2000; 68:13.</a></li><li><a class="nounderline abstract_t">Seidegård J, Randvall G, Nyberg L, Borgå O. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. Pharmazie 2009; 64:461.</a></li><li><a class="nounderline abstract_t">Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005; 21:363.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021324s016lbl.pdf (Accessed on August 23, 2018).</li><li><a class="nounderline abstract_t">Sandborn WJ, Bosworth B, Zakko S, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 2015; 148:740.</a></li><li><a class="nounderline abstract_t">Lindgren S, Löfberg R, Bergholm L, et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol 2002; 37:705.</a></li><li><a class="nounderline abstract_t">Tome J, Sehgal K, Kamboj AK, et al. Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study. Am J Gastroenterol 2022; 117:1311.</a></li><li><a class="nounderline abstract_t">Sherlock ME, MacDonald JK, Griffiths AM, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2015; :CD007698.</a></li><li><a class="nounderline abstract_t">Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331:842.</a></li><li><a class="nounderline abstract_t">Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998; 115:835.</a></li><li><a class="nounderline abstract_t">Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:113.</a></li><li><a class="nounderline abstract_t">Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2018; 113:481.</a></li><li><a class="nounderline abstract_t">D'Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998; 12:419.</a></li><li><a class="nounderline abstract_t">Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002; 97:915.</a></li><li><a class="nounderline abstract_t">Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331:836.</a></li><li><a class="nounderline abstract_t">Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183:796.</a></li><li><a class="nounderline abstract_t">Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.</a></li><li><a class="nounderline abstract_t">Skuladottir H, Wilcox A, McConnaughey R, et al. First-trimester nonsystemic corticosteroid use and the risk of oral clefts in Norway. Ann Epidemiol 2014; 24:635.</a></li><li><a class="nounderline abstract_t">Odufalu FD, Long M, Lin K, et al. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut 2022; 71:1766.</a></li><li><a class="nounderline abstract_t">Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis 2009; 15:25.</a></li></ol></div><div id="topicVersionRevision">Topic 4061 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27157244" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Budesonide for the treatment of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784947" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Oral locally active steroids in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355126" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355126" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355126" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355126" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24523594" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10945311" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19694184" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15709986" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15709986" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644096" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12126250" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35417427" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26497719" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Oral budesonide for induction of remission in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8078530" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A comparison of budesonide with prednisolone for active Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9753485" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15704045" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610508" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : ACG Clinical Guideline: Management of Crohn's Disease in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663720" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12003427" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8078529" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482652" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Corticosteroid use during pregnancy and risk of orofacial clefts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11091360" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25127739" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : First-trimester nonsystemic corticosteroid use and the risk of oral clefts in Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34686575" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18680195" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Budesonide induction and maintenance therapy for Crohn's disease during pregnancy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
